Phase 2 Brain Cancer Trial, Recruiting NCT05872347 Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT05872347
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to take part voluntarily, fully understand the study, and are willing to sign a consent form.
  • People who are generally well enough to carry out daily activities with little to no limitation (based on a standard fitness scale scored 0 or 1).
  • People with a life expectancy of at least 3 months.
  • People with locally advanced or metastatic breast cancer that cannot be treated with surgery or other local treatments.
  • People who have at least one tumour that can be measured on scans.
  • People whose blood and organ function test results meet the study's required levels.
  • People who agree to use effective contraception during the study.

Who may not be able to join:

  • People who have inflammatory breast cancer.
  • People the treating doctor considers unsuitable for hormone-based cancer therapy.
  • People with a history of another cancer diagnosis before the study begins.
  • People who are taking anti-tumour traditional Chinese patent medicines at the time of signing the consent form.
  • People who have had surgery before the study begins and have not yet fully recovered from it.
  • People who have already taken part in another clinical trial and received an experimental drug before this study begins.
  • People who are pregnant or breastfeeding.
  • People with a history of heart attack, unstable chest pain, serious heart rhythm problems, heart failure, certain abnormal heart readings on an ECG, or reduced heart pumping function before the study begins.
  • People with a history of stroke or serious blood clot conditions before the study begins.
  • People with active or insufficiently controlled hepatitis B, hepatitis C, or HIV infection.
  • People with a history of severe allergies or known allergy to any ingredient in the study drug.
  • People with conditions that may affect how they take medication or how their body absorbs it through the digestive system.
  • People with an infection that is not under control at the time the study begins.
  • People with a known history of drug or alcohol misuse, illegal drug use, or a confirmed neurological or psychiatric condition.
  • People the treating doctor determines have other health conditions where the risks of the study treatment outweigh the potential benefits, or who are otherwise considered ineligible for any reason assessed by the treating doctor.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 0086-020-87343811

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Registry
ClinicalTrials.gov
Start date
19 September 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Intracranial Objective response rate(iORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov